by Arthur Allen Credit: CC0 Public Domain For two decades, patients and physicians eagerly awaited a lower-cost version of the world’s bestselling drug, Humira, while its maker, AbbVie, fought off potential competitors by building a wall of more than 250 patents around it. When the first Humira biosimilar—essentially a generic version—finally hit the market in...
